Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France

European Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2014, Pages 429-436

  Bezin, J ^a,b,c,d   Pariente, A ^a,b,c,d   Lassalle, R ^a,b   Dureau Pournin, C ^a,b   Abouelfath, A ^a,b   Robinson, P ^a,b   Moore, N ^a,b,c,d   Droz Perroteau, C ^a,b,c   Fourrier Reglat, A ^a,b,c,d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c INSERM U657   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Acute coronary syndrome; Cohort study; persistence; Reimbursement database; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; COMORBIDITY; DRUG COMBINATION; FEMALE; FOLLOW UP; FRANCE; HEALTH INSURANCE; HEART INFARCTION; HUMAN; ICD-10; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; REIMBURSEMENT; SECONDARY PREVENTION; PRACTICE GUIDELINE; PROCEDURES;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION;

EID: 84896490389     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1614-5     Document Type: Article

References (30)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999-3054. doi:10.1093/eurheartj/ehr236
2. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569-2619. doi:10.1093/eurheartj/ehs215
3. Theroux P, Fuster V (1998) Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 97(12):1195-1206 (Pubitemid 28152893)
4. Haute Autorité de Santé (2007) Guide - Affection de Longue Durée Maladie coronarienne.
5. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31(20):2501-2555. doi:10.1093/eurheartj/ehq277
6. Kuepper-Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R et al (2012) Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. Aprospective cohort study based on claims data. Eur J Clin Pharmacol 68(10):1451-1460. doi:10.1007/s00228-012-1274-x
7. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED et al (2006) Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 166(17):1842-1847. doi:10.1001/archinte.166.17.1842 (Pubitemid 44455166)
8. Ringback Weitoft G, Ericsson O, Lofroth E, Rosen M (2008) Equal access to treatment? Population-based follow-up of drugs dispensed to patients after acute myocardial infarction in Sweden. Eur J Clin Pharmacol 64(4):417-424. doi:10.1007/s00228-007-0425-y
9. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P et al (2006) Long-term compliance with beta-blockers, angiotensinconverting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27(10):1153-1158. doi:10.1093/eurheartj/ehi705
10. Tuppin P, Neumann A, Danchin N, Weill A, Ricordeau P et al (2009) Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Arch Cardiovasc Dis 102(4):279-292. doi:10.1016/j.acvd.2009.02.005
11. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A et al (2010) Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 103(6-7):363-375. doi:10.1016/j.acvd. 2010.05.003
12. Danchin N, Cambou JP, Hanania G, Kadri Z, Genes N et al (2005) Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 150(6):1147-1153. doi:10.1016/j.ahj.2005. 01.058 (Pubitemid 41773515)
13. Lee HY, Cooke CE, Robertson TA (2008) Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manage Care Pharm JMCP 14(3):271-280 (Pubitemid 351711978)
14. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED (2006) Long-termadherence with cardiovascular drug regimens. Am Heart J 151(1):185-191. doi:10.1016/j.ahj.2005.02.038
15. Bourdes V, Ferrieres J, Amar J, Amelineau E, Bonnevay S et al (2011) Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput 49(8):947-955. doi:10.1007/s11517-011-0785-4
16. Amar J, Ferrieres J, Cambou JP, Amelineau E, Danchin N (2008) Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Arch Cardiovasc Dis 101(5):301-306. doi:10.1016/j.acvd.2008. 04.005
17. Ali RC, Melloni C, Ou FS, Schmader K, Ohman EM et al (2009) Age and persistent use of cardiovascular medication after acute coronary syndrome: results frommedication applied and sustained over time. J Am Geriatr Soc 57(11):1990-1996. doi:10.1111/j.1532-5415.2009.02483.x
18. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K et al (2007) Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 154(6):1108-1115. doi:10.1016/j.ahj.2007.07.040 (Pubitemid 350123528)
19. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA et al (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55(3):644-653. doi:10.1007/s00125-011-2429-5
20. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y (2010) French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 58(4):286-290. doi:10.1016/j.respe.2010.04. 005
21. De Roquefeuil L, Studer A, Neumann A, Merlière Y (2009) The Echantillon généraliste de bénéficiaires: representativeness, scope and limits]. Prat Organ Soins 40(3):213-223
22. Bagnall AJ, Yan AT, Yan RT, Lee CH, Tan M et al (2010) Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 3(5):530 - 537. doi:10.1161/CIRCOUTCOMES.109.919415
23. Fung V, Sinclair F, Wang H, Dailey D, Hsu J et al (2010) Patients' perspectives on nonadherence to statin therapy: a focus-group study. Permanent J 14(1):4-10
24. Byrne M, Walsh J, Murphy AW (2005) Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour. J Psychosom Res 58(5):403-415. doi:10.1016/j.jpsychores.2004.11.010 (Pubitemid 40982202)
25. Ross S, Walker A, MacLeod MJ (2004) Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens 18(9):607-613. doi:10.1038/sj.jhh.1001721 (Pubitemid 39232344)
26. Lambert-Kerzner A, Del Giacco EJ, Fahdi IE, Bryson CL, Melnyk SD et al (2012) Patient-centered adherence intervention after acute coronary syndrome hospitalization. Circ Cardiovasc Qual Outcomes 5(4):571-576. doi:10.1161/CIRCOUTCOMES.111.962290
27. Bailey TC, Noirot LA, Blickensderfer A, Rachmiel E, Schaiff R et al (2007) An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 167(6):586-590. doi:10.1001/archinte.167.6.586
28. Noize P, Bazin F, Dufouil C, Lechevallier-Michel N, Ancelin ML et al (2009) Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 18(4):310-319. doi:10.1002/pds.1717
29. Campeau L (1976) Letter: Grading of angina pectoris. Circulation 54(3):522-523
30. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565-574. doi:10. 1002/pds.1230, discussion 575-567